Skip to main content
Premium Trial:

Request an Annual Quote

FDA Licenses GeneGo s MetaCore Data Analysis Platform

NEW YORK, Oct. 10 (GenomeWeb News) - GeneGo has licensed its MetaCore data analysis platform to the US Food and Drug Administration for research and reviewing genomics data, the St. Joseph, Mich.-based company said today.


Under the agreement, GeneGo will integrate MetaCore with the FDA's ArrayTrack microarray analysis software and make it available to FDA researchers.


"Since MetaCore is already being applied in drug discovery by our pharmaceutical customers for a couple of years now, it is logical that it will also be used on the regulatory side as well," said GeneGo vice president of business development Julie Bryant in a company statement.


MetaCore allows researchers to visualize, map, and network several types of data, including gene expression, RNAi, proteomic, metabolomic, SAGE and SNP data.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.